Evidence map›Paper›PMID 20035613›Full record

ArticleAssay and drug development technologies2010

Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.

Imran H Khan, Jing Zhao, Paramita Ghosh, Melanie Ziman, Colleen Sweeney, Hsing-Jien Kung, Paul A Luciw

Abstract read
In one paragraph

Article in Assay and drug development technologies, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Imran H KhanCenter for Comparative Medicine, University of California at Davis, Hutchison Drive and County Road 98, Davis, CA 95616, USA. ihkhan@ucdavis.edu
Jing Zhao
Paramita Ghosh
Melanie Ziman
Colleen Sweeney
Hsing-Jien Kung
Paul A Luciw
VA Northern California Health Care System · USUniversity of California, Davis · US

Funding

Rapamycin Regulation of the Androgen Receptor: Implications in Prostate CancerR01CA133209 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GHOSH, PARAMITA M. · 2009 to 2013
$1.1M
NCI NIH HHS R01 CA133209
6 · The paper itself

Abstract

Receptor tyrosine kinases (RTKs) in the ErbB family (EGFR, ErbB2, ErbB3, and ErbB4) are implicated in a variety of human malignancies. Accordingly, determination of both expression and activation (dimerization/heterodimerization and phosphorylation) of ErbB proteins is critical in defining their functional role in cancer. Efficient and comprehensive methods to study molecular functions of ErbB family of RTKs are needed not only for improvements in diagnostics but also for early screening of targeted drugs (eg, small molecule inhibitors and therapeutic antibodies). We report development of 3 multiplex microbead immunoassays for simultaneous detection of expression, protein-protein interactions, and phosphorylation of these RTKs. These novel multiplex immunoassays were used to study ErbB RTKs under different cell activation conditions in 2 breast cancer cell lines (MDA-MB-453 and MDA-MB-468) and an epidermoid cancer cell line (A431). The results were confirmed by immunoprecipitation/western blot. Importantly, the multiplex immunoassay facilitated time-course studies in these cell lines after cell activation with EGF and neuregulin, revealing the kinetics of phosphorylation of the ErbB family RTKs. This study demonstrates the utility of the Luminex(R) multiplex system as an efficient and comprehensive approach to study different aspects of molecular roles of these RTKs. Importantly, the study provides proof-of-concept for the utility of the multiplex microbead immunoassay approach for potential use in efficient, robust, and rapid screening of drugs, particularly those targeting functional aspects of these potent signaling molecules. In addition, the assays described here may be useful for cancer diagnostics and monitoring efficacy of therapy targeting the ErbB family of RTKs.

Indexed as

Breast NeoplasmsEnzyme ActivationEpidermal Growth FactorErb-b2 Receptor Tyrosine KinasesErbB ReceptorsFemaleHumansNeuregulin-1PhosphorylationProtein Array AnalysisProtein MultimerizationReceptor, ErbB-3Receptor, ErbB-4Receptor Protein-Tyrosine KinasesEpidermal Growth FactorErb-b2 Receptor Tyrosine KinasesERBB4 protein, humanErbB ReceptorsNeuregulin-1Receptor, ErbB-3Receptor, ErbB-4Receptor Protein-Tyrosine Kinases

Identifiers

PMID20035613
PMCPMC3196214
OpenAlexW1967102877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.